Technology & Science
Apr. 9, 2010
Biotech M&A Activity on the Rise
The window is starting to open for venture capital-backed biotechnology firms to enter the public markets or merge with other companies, but it's still a tight squeeze.
Daily Journal Staff Writer
The window is starting to open for venture capital-backed biotechnology firms to enter the public markets or merge with other companies, but it's still a tight squeeze.
In the first quarter of 2010, U.S. venture-backed initial public offerings had their best quarter since the fourth quarter of 2007 and venture-backed mergers and acquisitions had their best quarter on record since ...
For only $95 a month (the price of 2 article purchases)
Receive unlimited article access and full access to our archives,
Daily Appellate Report, award winning columns, and our
Verdicts and Settlements.
Or
$795 for an entire year!
Or access this article for $45
(Purchase provides 7-day access to this article. Printing, posting or downloading is not allowed.)
Already a subscriber?
Sign In